What went well
- Announced positive topline results in May 2025 from the randomized, controlled Phase 2 Actuate-1801 trial of lead candidate elraglusib plus gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic cancer, which met its primary endpoint with a statistically significant median overall survival benefit (10.1 vs 7.2 months, HR=0.63, log-rank p=0.01), a 12-month survival rate of 44.1% versus 22.3% (p=0.0005) and a 37% reduction in the risk of death versus GnP alone.
- Reported a favorable safety profile for the elraglusib/GnP combination, with treatment-related adverse events mostly Grade 1-2 and the most common being transient, reversible visual disturbances.
- Completed the Phase 1/2 Actuate-1902 study in refractory pediatric malignancies in July 2025, which identified Ewing sarcoma as a potential second indication for elraglusib.
- Narrowed net loss to $5.9 million from $6.6 million a year earlier as research and development expense fell to $2.8 million (from $4.4 million) with the pivotal Phase 2 mPDAC trial completing enrollment.
What went wrong
- Ended June 30, 2025 with only $6.5 million in cash and cash equivalents and a $2.5 million working-capital deficit; management and its auditors flagged substantial doubt about the company's ability to continue as a going concern, with existing cash projected to fund operations only into October 2025 without additional capital.
- General and administrative expense rose to $3.2 million from $1.1 million a year earlier, reflecting public-company costs following the August 2024 IPO.
- Remained dependent on dilutive financings, including a June 2025 private placement (net proceeds of about $4.6 million) and sales under the B. Riley committed equity facility.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| Cash runway | As of June 30, 2025 | $6.5M in cash; management projected existing cash would not fund operations beyond October 2025 without raising additional capital |
| Ewing sarcoma program | 2026 | Plans to advance elraglusib toward a Phase 2 study in relapsed/refractory Ewing sarcoma in 2026, subject to available funding |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Research & development expense | $2.8M (vs $4.4M) | Lower spend as the Phase 2 Actuate-1801 mPDAC trial completed enrollment. |
| General & administrative expense | $3.2M (vs $1.1M) | Higher public-company, professional and personnel costs following the August 2024 IPO. |
| Net loss | $5.9M (vs $6.6M) | Lower R&D more than offset higher G&A. |
| Diluted net loss per share | $(0.30) | Loss per share on 19.6M weighted-average shares outstanding. |
| Cash & cash equivalents | $6.5M | Thin runway at June 30, 2025; working-capital deficit of $2.5M. |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| mPDAC Phase 2 (Actuate-1801) | Enrollment completed; awaiting data | Topline announced May 2025 - met primary OS endpoint | Up |
| Cash position / going concern | Post-IPO capital | $6.5M cash; going-concern doubt; runway into October 2025 | Down |
| Pediatric program | Phase 1/2 ongoing | Study completed; Ewing sarcoma identified as second indication | Up |
More on Actuate Therapeutics, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.